Impact of quadruple eradication therapy on the elements of the Sydney system in chronic Helicobacter pylori gastritis in Abidjan (Ivory Coast)
Nigerian Journal of Gastroenterology and Hepatology · Volume 13, Issue 2 (2021) · pp. 40–46
Abstract
<jats:sec>
<jats:title>Background:</jats:title>
<jats:p>The effect of eradicating <jats:italic toggle="yes">Helicobacter pylori</jats:italic> on the course of chronic gastritis (CG) is controversial. The aim of this study was to assess the impact of <jats:italic toggle="yes">H. pylori</jats:italic> eradication treatment on CG.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Materials and Methods:</jats:title>
<jats:p>This was a retrospective (January 2016 to December 2018) multicenter study. All medical records of patients treated with a quadruple therapy to eradicate <jats:italic toggle="yes">H. pylori</jats:italic> who were confirmed with histology at least 4 weeks after the end of treatment were included. The evolution of the CG ratings after treatment was analyzed.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results:</jats:title>
<jats:p>The records of 170 patients (male/female ratio 0.95, average age 49.3 ± 12.2 years) were included. Respectively, inflammation and <jats:italic toggle="yes">H. pylori</jats:italic> levels decreased (<jats:italic toggle="yes">P</jats:italic> < 0.001) in antrum (2.09 to 1.45; 1.95 to 0.63) and fundus (1.82 to 1.27; 1.76 to 0.55). Gastric atrophy levels regressed in antrum (0.28 to 0.18; <jats:italic toggle="yes">P</jats:italic> = 0.0655) and fundus (0.19 to 0.09; <jats:italic toggle="yes">P</jats:italic> = 0.0096) on sequential quadruple therapy (0.42 to 0.26; <jats:italic toggle="yes">P</jats:italic> = 0.2384), with bismuth (0.27 to 0.1l8; <jats:italic toggle="yes">P</jats:italic> = 0.6232) or with concomitant therapy for 14 days (0.20 to 0.13; <jats:italic toggle="yes">P</jats:italic> = 0.1288). Gastric intestinal metaplasia progressed in the antrum (0.05 to 0.06; <jats:italic toggle="yes">P</jats:italic> = 0.5930) and the fundus (0.02 to 0.03; <jats:italic toggle="yes">P</jats:italic> = 0.2568); in sequential quadruple therapy (0.04 to 0.07; <jats:italic toggle="yes">P</jats:italic> = 0.3173) and in bismuth therapy groups (0.04 to 0.09; <jats:italic toggle="yes">P</jats:italic> = 0.5637) even after eradication of <jats:italic toggle="yes">H. pylori</jats:italic> (0.03 to 0.09; <jats:italic toggle="yes">P</jats:italic> = 0.0455).</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusions:</jats:title>
<jats:p>The eradication treatment for <jats:italic toggle="yes">H. pylori</jats:italic> improved elements of the Sydney CG system except for intestinal metaplasia.</jats:p>
</jats:sec>